CNBX leader in cancer related cannabinoid-based medicine

CNBX Cannabics Pharmaceuticals has an agreement with Purisys, a leading Active Pharmaceutical Iingredient manufacturer, to use its API in Phase I/II (a) clinical studies that it is planning to launch in 2022.

So this year will be quite bullish for CNBX

Cannabics Pharmaceuticals is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. It engages in the discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer.

52 Week Range 0.08 - 0.60
Market Cap 15.163M

Short term upside: $0.20
After they begin the Phase I/II (a) clinical studies, the stock can reach once again its 52 week highs.